SKL2001 NEW
| Price | $34 | $55 | $109 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: SKL2001 | CAS No.: 909089-13-0 |
| Purity: 99.5% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | SKL2001 |
| Description | SKL2001, an agonist of the Wnt/β-catenin pathway, can disrupt the Axin/β-catenin interaction. |
| Cell Research | The HEK293 reporter and control cell lines were established. The HEK293 reporter cells were inoculated into 384-well plates at 10 000 cells per well and grown for 24 h. Next, each compound in the chemical library (～270 000) was added to at a final concentration of 20 μM. After 15 h, the plates were assayed for firefly luciferase activity.(Only for Reference) |
| In vitro | SKL2001 upregulated β-catenin responsive transcription by increasing the intracellular β-catenin protein level and inhibited the phosphorylation of β-catenin at residues Ser33/37/Thr41 and Ser45, which would mark it for proteasomal degradation, without affecting CK1 and GSK-3β enzyme activities. SKL2001 disrupted the Axin/β-catenin interaction, which is a critical step for CK1- and GSK-3β-mediated phosphorylation of β-catenin at Ser33/37/Thr41 and Ser45. The treatment of mesenchymal stem cells with SKL2001 promoted osteoblastogenesis and suppressed adipocyte differentiation, both of which were accompanied by the activation of Wnt/β-catenin pathway. SKL2001 did not affect either NF-κB or p53 reporter activity and inhibits β-catenin phosphorylation without affecting GSK-3β activity[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (174.65 mM), Sonication is recommended. Ethanol : 53 mg/mL (185.1 mM) H2O : < 1 mg/mL (insoluble or slightly soluble) |
| Keywords | SKL2001 | Inhibitor | Wnt | Beta catenin | β-catenin | SKL-2001 | inhibit | SKL 2001 |
| Inhibitors Related | Urea | PRI-724 | Wnt pathway activator 1 | L-quebrachitol | MSAB | EMT inhibitor-1 | Wogonin | CHIR-99021 | XAV-939 | Nefopam hydrochloride | KY-05009 | Bisdemethoxycurcumin |
| Related Compound Libraries | Neural Regeneration Compound Library | Bioactive Compound Library | Anti-Ovarian Cancer Compound Library | Neuroprotective Compound Library | Anti-Fibrosis Compound Library | Stem Cell Differentiation Compound Library | Anti-Prostate Cancer Compound Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Neuronal Differentiation Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1.00/1ASSAYS |
VIP7Y
|
Career Henan Chemical Co
|
2019-09-05 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hills
INQUIRY